• Explore /
  • Poster
  • / KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

Abstract Poster

Authors

Christopher Hoimes

Christopher J. Hoimes

Duke University, Durham, NC

Christopher J. Hoimes , Jens Bedke , Yohann Loriot , Hiroyuki Nishiyama , Xiao Fang , Ritesh S. Kataria , Blanca Homet Moreno , Matt D. Galsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT04700124

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4587)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4587

Abstract #

TPS4587

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Arlene O. Siefker-Radtke

First Author: Christopher J. Hoimes

First Author: Terence W. Friedlander

First Author: Matt D. Galsky